Catalio Capital Management, a venture capital firm that invests in breakthrough biomedical technology companies, Third Rock Ventures, a healthcare venture firm, and Novo, a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation, led a $150m Series A funding round in Clasp Therapeutics, a biotechnology company, with participation from Vivo, Cure Ventures, Blackbird BioVentures, Pictet Alternative Advisors, American Cancer Society’s Bright Edge and Alexandria Venture Investments. “At Clasp we strive to help people with cancer lead longer and healthier lives by engaging each patient’s own immune cells to eradicate their cancer with absolute specificity. Clasp brings together leading researchers, clinicians and drug developers to develop groundbreaking cancer immunotherapies that are precise and potent, but without the toxicities commonly associated with on-target, off-tumor binding,” Robert Ross, Clasp Therapeutics CEO.